Antibodies specific for CLL-1

1. A method of treating a myeloproliferative disorder in an individual, wherein the myeloproliferative disorder is acute myeloid leukemia (AML), the method comprising

administering to the individual an antibody that binds to human C-type lectin like molecule 1 (CLL-1), wherein the antibody is selected from the group consisting of:

an antibody comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NOs:51, 59, and 67, and light chain CDRs of SEQ ID NOs:75, 83, and 91;

an antibody comprising heavy chain CDRs of SEQ ID NOs:52, 60, and 68, and light chain CDRs of SEQ ID NOs:76, 84, and 92; and

an antibody comprising heavy chain CDRs of SEQ ID NOs:53, 61, and 69 and light chain CDRs of SEQ ID NOs:77, 85, and 93,

thereby treating the myeloproliferative disorder in the individual.

2. The method of claim 1 , wherein the antibody is conjugated to a therapeutic compound.

3. The method of claim 1 , wherein the individual has been diagnosed with AML or has undergone therapy for AML.

4. The method of claim 1 , wherein the antibody is an IgG.

5. The method of claim 1 , wherein the antibody is a humanized, human, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, or grafted antibody.

6. The method of claim 1 , wherein the antibody is a bispecific antibody.

7. The method of claim 1 , wherein the antibody is a chimeric antibody.

8. The method of claim 1 , wherein the antibody is an antibody fragment selected from Fab, F(ab′)2, Fv, scFv, Fd and dAb.

9. The method of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 51, 59, and 67, and light chain CDRs of SEQ ID NOs: 75, 83, and 91.

10. The method of claim 9 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 4 and a light chain variable region of SEQ ID NO: 6.

11. The method of claim 9 , wherein the antibody is humanized.

12. The method of claim 9 , wherein the antibody is a fusion protein.

13. The method of claim 9 , wherein the antibody is a chimeric antibody in which the constant region is replaced so that the antigen binding site is linked to a different effector function.

14. The method of claim 9 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

15. The method of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 52, 60, and 68, and light chain CDRs of SEQ ID NOs: 76, 84, and 92.

16. The method of claim 15 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 10.

17. The method of claim 15 , wherein the antibody is humanized.

18. The method of claim 15 , wherein the antibody is a fusion protein.

19. The method of claim 15 , wherein the antibody is a chimeric antibody in which the constant region is replaced so that the antigen binding site is linked to a different effector function.

20. The method of claim 15 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.

21. The method of claim 1 , wherein the antibody comprises heavy chain complementarity determining regions (CDRs) of SEQ ID NOs: 53, 61, and 69 and light chain CDRs of SEQ ID NOs: 77, 85, and 93.

22. The method of claim 21 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 12 and a light chain variable region of SEQ ID NO: 14.

23. The method of claim 21 , wherein the antibody is selected from an immunoglobulin, antibody conjugate, or antibody fragment.

24. The method of claim 21 , wherein the antibody is humanized.

25. The method of claim 21 , wherein the antibody is a fusion protein.

26. The method of claim 21 , wherein the antibody is a chimeric antibody in which the constant region is replaced so that the antigen binding site is linked to a different effector function.

27. The method of claim 21 , wherein the antibody is conjugated to a therapeutic compound or a cytotoxic drug.